支架或球囊辅助弹簧圈栓塞技术对颈内动脉宽颈后交通动脉瘤的疗效

目的评估支架或球囊辅助弹簧圈栓塞技术对颈内动脉宽颈后交通动脉瘤的治疗效果和安全性。方法回顾性分析接受支架或球囊辅助弹簧圈栓塞的47例颈内动脉宽颈后交通动脉瘤患者,其中31例采用支架辅助治疗,16例采用球囊辅助治疗。治疗后随访6~36个月,分析患者的术后造影、并发症及临床情况。结果 47例中,采用支架或球囊两种辅助治疗方法相关并发症发生率分别为9.68%(3/31)和6.25%(1/16);手术后即刻造影显示完全栓塞率分别为58.06%(18/31)和68.75%(11/16)。31例支架辅助弹簧圈栓塞病例中随访造影18例,均无动脉瘤复发;16例球囊辅助弹簧圈栓塞病例中随访造影10例,其中3例复发。结论支架辅助弹簧圈栓塞技术和球囊辅助弹簧圈栓塞技术是颈内动脉宽颈后交通动脉瘤安全有效的治疗方法。支架辅助弹簧圈栓塞技术能够显著降低颈内动脉宽颈后交通动脉瘤的复发率,但有增加缺血事件的风险。球囊辅助弹簧圈栓塞技术的手术操作相关并发症低,术后完全栓塞率高,但复发率也相对较高。     

多支架辅助弹簧圈栓塞治疗颈内动脉血泡样动脉瘤效果及其对血管内皮功能的影响

目的探讨多支架辅助弹簧圈栓塞治疗颈内动脉血泡样动脉瘤(BBA)的效果及其对患者血管内皮功能的影响。方法对31例颈内动脉BBA患者行多支架辅助弹簧圈栓塞治疗。于术后当天采用Raymand分级评价栓塞效果;术后28天及术后3个月采用改良Rankin量表(mRS)评价患者预后,通过统计学方法对比分析术前及术后1周患者外周血血浆内皮素-1(ET-1)、血管性假血友病因子(vWF)及血清一氧化氮(NO)水平。结果多支架辅助弹簧圈栓塞治疗技术成功率为93.55%(29/31)。29例顺利完成BBA栓塞,术后当天Raymand分级显示栓塞治疗有效(Ⅰ、Ⅱ级)率为100%(29/29,其中Ⅰ级22例、Ⅱ级7例);术后28天及术后3个月mRS显示预后良好(0～2级)率分别为68.97%(20/29,其中0级5例、1级8例、2级7例)和75.86%(22/29,其中0级7例、1级12例、2级3例)。与术前相比,31例患者术后1周ET-1[(518.38±22.91)pg/ml vs (550.32±28.57)pg/ml,t=-4.848,P0.001]、vWF[(1.66±0.20)ng/ml vs (1.86±0.29)ng/ml,t=-3.161,P=0.002]均明显升高,而血清NO水平明显降低[(37.40±4.88)nmol/ml vs (33.02±4.24)nmol/ml,t=3.796,P0.001]。结论多支架辅助弹簧圈栓塞治疗颈内动脉BBA疗效肯定,但对患者术后血管内皮功能有一定不利影响。     

颅内分叉部动脉瘤复发后行支架辅助栓塞再治疗的临床效果

目的探讨初次行单纯弹簧圈栓塞或开颅夹闭术治疗后复发的颅内分叉部动脉瘤患者行支架辅助栓塞再治疗的可行性及有效性。方法回顾性分析2009年3月至2019年11月复旦大学附属华山医院放射科介入组收治的初次行单纯弹簧圈栓塞或开颅夹闭术治疗后复发并接受支架辅助栓塞再治疗的20例颅内分叉部动脉瘤患者的临床资料。男性9例,女性11例,中位年龄55.5岁(范围:33~71岁);首次治疗行单纯弹簧圈栓塞17例、开颅夹闭术3例;复发后15例行单支架辅助栓塞治疗,5例行Y形双支架辅助栓塞治疗。收集患者围手术期情况、术后并发症及预后情况。采用Mann-Whitney U检验对患者初次及再次治疗后的随访时间进行比较;采用t检验对再次治疗前、术后即刻及末次随访时近端载瘤动脉主干与支架侧分支的夹角大小进行比较。结果20例患者中,18例(90.0%)患者术后即刻脑血管造影示致密栓塞(RaymondⅠ型),2例(10.0%)示瘤颈少许残余(RaymondⅡ型),术后随访[M(QR)]8.5(16.3)个月,与初次治疗后随访时间的15.5(27.0)个月相比,差异无统计学意义(U=157.7,P=0.25)。随访期间2例患者复发,均为术后即刻瘤颈少许残余病例,其中1例为Y形双支架辅助栓塞病例。围手术期发生症状性缺血6例,其中4例为Y形双支架辅助栓塞病例;未发生围手术期出血等并发症,无手术相关的永久性致残及死亡病例。术后即刻和末次随访时载瘤动脉主干与支架所在分支成角分别为(115.4±28.9)°和(132.6±26.8)°,均较术前的(90.1±21.1)°明显增大(t=5.14,P<0.01;t=7.78,P<0.01)。结论初次弹簧圈栓塞或开颅夹闭术后复发的颅内分叉动脉瘤患者再次接受支架辅助栓塞是可行的,动脉瘤再复发率较低。     

Lvis支架与Enterprise支架辅助栓塞颅内宽颈动脉瘤的比较

目的比较Lvis支架和Enterprise支架辅助弹簧圈栓塞颅内宽颈动脉瘤的安全性和有效性。方法回顾性比较Lvis或Enterprise支架辅助弹簧圈栓塞颅内宽颈动脉瘤212例(214个动脉瘤),其中Lvis组88例(90个动脉瘤),Enterprise组124例(124个动脉瘤),比较2组动脉瘤栓塞即刻及随访时栓塞程度Raymond分级、围术期并发症、mRS评分。结果 Lvis组置入支架90个,Enterprise组124个。术后即刻DSA:Lvis组RaymondⅠ级77.3%(68/88),Ⅱ级13.6%(12/88),Ⅲ级9.1%(8/88);Enterprise组RaymondⅠ级75.8%(94/124),Ⅱ级15.3%(19/124),Ⅲ级8.9%(11/124),2组比较差异无显著性(Z=-0.214,P=0.830)。术后随访复查DSA:Lvis组RaymondⅠ级90.4%(76/84),Ⅱ级4.8%(4/84),Ⅲ级2.4%(2/84),2例术后6个月复发;Enterprise组RaymondⅠ级72.8%(86/118),Ⅱ级15.3%(18/118),Ⅲ级8.5%(10/118),4例术后6个月复发,2组比较差异有显著性(Z=-3.312,P=0.002)。围手术期支架相关并发症发生率Lvis组11.4%(10/88),与Enterprise组5.6%(7/124)比较无统计学差异(χ~2=2.282,P=0.131)。2组术后6个月mRS评分0～2分Lvis组85.2%(75/88),Enterprise组78.2%(97/124),2组比较差异无显著性(Z=-1.145,P=0.252)。结论 Lvis支架和Enterprise支架辅助弹簧圈栓塞治疗颅内宽颈动脉瘤安全、有效。     

脾动脉瘤血管腔内治疗的临床疗效分析

目的探讨血管腔内治疗脾动脉瘤的安全性和有效性。方法回顾性分析2010年1月至2014年12月本科收治的48例脾动脉瘤患者的资料,腔内治疗方法:弹簧圈动脉瘤(14例)或载瘤动脉栓塞术(19例),覆膜支架隔绝术(2例),支架辅助弹簧圈瘤体内填塞(5例)和多层裸支架隔绝术(8例)。术后1、3、6、12个月采用CT血管造影检查随访,记录并评价围手术期和随访期的临床结果指标。结果本组病例瘤体均治疗成功,支架植入患者的脾动脉均通畅。围手术期无手术相关死亡,8例患者弹簧圈栓塞后出现栓塞后综合征,均于3~5天后缓解。随访时间23.9(3~59)个月,采用弹簧圈栓塞瘤体或载瘤动脉33例:4例患者发现有部分脾脏梗死,但无明显临床症状,2例患者因瘤体内再灌注接受再次手术;采用覆膜支架植入或裸支架辅助弹簧圈栓塞7例:动脉瘤隔绝或栓塞良好,无内漏,支架通畅;采用多层裸支架隔绝术8例:术后12个月6例(75%)患者瘤腔达到完全血栓化,分支动脉通畅。其余病例未出现严重并发症。随访期患者均未观察到动脉瘤增大、破裂或复发。结论血管腔内治疗脾动脉瘤安全,疗效显著。     

肺部体循环动脉CTA在咯血介入治疗中的应用

目的探讨肺部体循环CTA在咯血介入栓塞治疗中寻找靶血管中的应用价值。方法将48例咯血患者根据介入栓塞术前是否行CTA检查分为CTA组(n=27)和DSA组(n=21)。CTA组术前行肺部体循环CTA检查,将重建图像传至工作站进行后处理,采用MPR、MIP和VR显示可能参与病灶区供血的动脉,根据CTA图像行DSA及介入栓塞治疗。DSA组直接行DSA及介入栓塞治疗。记录支气管动脉开口位置,比较两组术中透视时间、短期(1个月内)和长期(1个月~1年)复发率。结果对48例咯血患者均成功栓塞。CTA组和DSA组术中透视时间分别为(31.29±6.37)min、(36.61±7.49)min,差异有统计学意义(t=-2.658,P0.05)。CTA组和DSA组短期复发率分别3.70%(1/27)、28.57%(6/21),差异有统计学意义(χ2=5.864,P=0.022);长期复发率分别为7.41%(2/27)、14.29%(3/21),差异无统计学意义(χ2=0.599,P=0.379)。所有患者均未出现截瘫、皮肤局部坏死、异位栓塞等严重并发症。结论肺部体循环CTA可准确定位支气管动脉栓塞术中的出血动脉,缩短手术时间,降低短期复发率,为介入手术方案的制定提供重要信息。     

支架辅助弹簧圈栓塞在急诊栓塞颅内宽颈微小动脉瘤破裂中的应用

目的探讨支架辅助弹簧圈栓塞在治疗急诊治疗颅内破裂宽颈微小动脉瘤(最大径≤3mm)中的操作技巧及临床疗效。方法回顾急诊支架辅助弹簧圈栓塞治疗的7例颅内破裂宽颈微小动脉瘤患者资料,分析治疗方法、疗效、并发症、预后及6~12个月随访结果,评价支架技术的安全性、有效性及操作技巧。结果术后即刻造影显示,完全栓塞5例,次全栓塞1例,单纯植入支架1例;未发生破裂出血及血栓栓塞事件。术后3个月改良式格拉斯哥预后评分(GOS)结果显示,6例恢复正常,1例恢复良好。6~12个月随访未发现动脉瘤再破裂出血。结论支架辅助弹簧圈急诊栓塞治疗颅内破裂宽颈微小动脉瘤安全有效。     

采用不同栓塞材料的支气管动脉栓塞术治疗大咯血的疗效分析

目的探讨在支气管动脉栓塞术（BAE）中采用不同栓塞材料治疗大咯血的临床疗效。方法对59例内科治疗无效的大咯血患者,于术前常规CTA后行BAE;对其中18例单纯应用明胶海绵（GS组）,41例应用海藻酸钠微球（KMG）联合GS或弹簧圈（KMG组）进行栓塞。所有病例随访12个月以上,并对疗效进行对比分析。结果对所有患者均成功实施BAE。58例患者BAE术后24h内停止咯血,有效率98.31%（58/59）。12个月内9例复发咯血（GS组6例,KMG组3例）,总复发率15.25%（9/59）。术后3个月内两组各2例患者复发咯血,复发率差异无统计学意义;术后3～12个月KMG组复发率（1/41,2.44%）低于GS组（4/18,22.22%,P=0.03）。结论 BAE术中合理选择栓塞材料可有效降低术后大咯血的复发率。     

个体化血管内介入治疗椎动脉夹层动脉瘤

目的观察个体化血管内介入治疗椎动脉夹层动脉瘤(VADA)的临床效果。方法回顾性分析38例VADA患者(43枚动脉瘤)。其中10例(10枚)动脉瘤破裂出血,对6枚采用动脉瘤填塞及载瘤动脉闭塞术,4枚以单支架辅助弹簧圈栓塞。对未破裂33枚动脉瘤均行载瘤动脉重建术,以单支架辅助弹簧圈栓塞3枚,双支架辅助弹簧圈栓塞25枚,三支架辅助弹簧圈栓塞5枚。结果血管内介入治疗所有43枚VADA均获成功,对28枚实现完全及次全栓塞、15枚实现部分栓塞。术后随访12个月,34例(38枚动脉瘤)接受全程复查,其中21枚治愈、11枚改善、6枚稳定,未见复发,无新发脑出血或脑缺血症状;改良Rankin量表(mRS)评分0～1分30例,2分2例,3分1例,4分1例。结论根据具体情况采用个体化血管内介入治疗VADA安全、有效,且预后较好。     

开颅手术夹闭与血管内介入栓塞治疗破裂颅内动脉瘤疗效比较

目的对比开颅手术夹闭与血管内介入栓塞治疗破裂颅内动脉瘤疗效。方法破裂颅内动脉瘤患者68例采用随机平行对照法将其分为两组,A组给予开颅夹闭,B组给予血管内栓塞。结果 B组患者手术耗时、术中出血量、住院时间均优于A组,数据对比差异有统计学意义(P0.05),而B组患者平均费用高于A组,数据对比差异有统计学意义(P0.05)。两组治疗良好率差异无统计学意义(χ2=0.469,P=0.693);A组术后并发症发生率为24.24%(8/33)、复发率为9.09%(3/33),B组分别为6.06%(2/33)、30.30%(10/33),两组比较差异均有统计学意义(χ2=4.243、4.694,P=0.039、0.030)。结论对破裂颅内动脉瘤患者,给予血管内介入栓塞治疗具有创伤小、术后恢复快等优点,但是其复发率及花费较高,临床上需要结合患者实际情况有针对性的选择手术方式。     

支架辅助栓塞未破裂颅内动脉瘤术后颅内微缺血危险因素

目的分析支架辅助栓塞(SAE)治疗未破裂颅内动脉瘤后发生颅内微缺血(IMI)的危险因素。方法回顾性分析236例接受SAE治疗的未破裂颅内动脉瘤患者,根据术后3天内头部MR弥散加权成像(DWI)检查结果判断是否发生IMI;采用单因素分析和多因素Logistic回归分析筛选IMI危险因素。结果 236例中,97例(97/236, 41.10%)发生IMI(IMI组),139例未发生IMI(非IMI组,n=139)。2组间合并糖尿病、缺血性卒中病史、血小板抑制不足、前交通动脉瘤、伴瘤内附壁血栓、支架贴壁不良及微弹簧圈襻疝出瘤囊差异有统计学意义(P均0.05)。多因素Logistic回归分析结果显示,血小板抑制不足、前交通动脉瘤、伴瘤内附壁血栓、支架贴壁不良及微弹簧圈襻疝出瘤囊是IMI的独立危险因素(P均0.05)。结论 SAE治疗未破裂颅内动脉瘤后可发生IMI;血小板抑制不足、前交通动脉瘤、伴瘤内附壁血栓、支架贴壁不良及微弹簧圈襻疝出瘤囊促进IMI发生。     

Clinical and angiographic outcome of intracranial aneurysms treated with Matrix detachable coils in Chinese patients

BACKGROUND: Aneurysm recurrence is an innate problem in endovascular treatment of aneurysms with coils. A coated coil system named Matrix (Boston Scientific Neurovascular, Fremont, CA), covered with a bioabsorbable polymeric material (polyglycolide/lactide copolymer [PGLA]), was developed to accelerate intraaneurysmal clot organization and fibrosis. The purpose of this study was to evaluate the efficacy and safety of the Matrix detachable coils in patients with intracranial aneurysms and aneurysmal recurrence rate. METHODS: In a regional neurosurgical center in Hong Kong, data of patients undergoing endovascular embolization of intracranial aneurysm was collected. In a 20-month period, 42 patients with 44 aneurysms were treated by endovascular embolization using matrix coils alone or mixed with bare platinum coils. Thirty-four patients presented with ruptured aneurysms, and 8 patients presented with unruptured aneurysms. RESULTS: Twenty-five patients (60%) had 6-month follow-up DSA, and 10 patients (24%) had 18-month follow-up DSA. Seven aneurysm recurrences were identified, amounting to 16% for all aneurysms and 14% for ruptured aneurysms. Four patients were treated by repeated embolization, and 2 patients were treated by microsurgical clipping. Two adverse events due to thromboembolism were noted. One 78-year-old lady with poor-grade subarachnoid hemorrhage treated by partial embolization died from rebleed at day 4. Another patient with partial embolization and spontaneous thrombosis of dorsal wall ICA aneurysm died at 2 months with aneurysm recanalization with rerupture. Twenty-six patients achieved favorable outcome (GOS score 4 or 5) at last follow-up. The aneurysm recurrence rate using bare platinum coils of the same center was 11% and 7% for all aneurysms and ruptured aneurysms, respectively. CONCLUSION: Matrix coil embolization was safe, but there was no reduction in aneurysm recurrence using matrix coils alone or mixed with GDCs, compared with GDCs alone.     

Application of the Willis covered stent in the treatment of internal carotid artery blood blister-like aneurysms

The optimal treatment for blood blister-like aneurysm (BBA) has not yet been determined, and BBA has a high recurrence rate after stent-assisted embolization. The purpose of the present study was to evaluate the safety and feasibility of patients with BBA rupture in the acute phase or patients with BBA who have recurrence after stent-assisted coil embolization. Eight patients (8 women, mean age 50.3?±?3.7 years) who presented with ruptured BBA or recurrence BBA that had been treated by stent-assisted embolization (5 patients after primary treatment of stent-assisted embolization) were retrospectively reviewed. Clinical follow-up was performed at 1 year after endovascular treatment. All patients were successfully treated with the WCS, and immediate postoperative angiography showed that the aneurysms were completely isolated. The ophthalmic artery was covered by WCS in one patient; however, this patient did not show any clinical visual field or vision symptoms. Procedure-related complications such as aneurysm rupture, vasospasm, acute thrombosis, or thromboembolism did not occur in any case. All patients were followed up for 1 year after endovascular treatment, and they were in good condition without recurrence. One patient developed delayed bleeding at the right temporal lobe. All patients had good clinical prognosis (modified Rankin Scale score?≤?2). WCS implantation may be a safe and feasible strategy for patients with BBA rupture in the acute phase and patients with BBA who have recurrence after stent-assisted coil embolization and is a promising option worth exploring.

     

Pipeline flow diversion with adjunctive coil embolization for internal carotid artery aneurysms following an intradural component: results in 46 consecutive aneurysms from a Japanese single-center experience

In the treatment of an intracranial aneurysm with the flow diverter, the combined use of coil embolization can help promote subsequent progressive thrombosis within the aneurysm sac and reduce the risk of delayed aneurysm rupture. This study retrospectively reviewed outcomes of patients who had undergone the Pipeline Embolization Device (PED) with adjunctive coil embolization (PED/coil) at a single center to determine its safety and efficiency. Patients with internal carotid artery aneurysms following an intradural component were selected for PED/coil between 2015 and 2020. All patients were premedicated with dual antiplatelet therapy of aspirin plus clopidogrel or prasugrel. A minimal number of PEDs were deployed, with coils inserted using a stent-jail technique, avoiding dense packing. A total of 46 aneurysms (43 patients; median dome size, 11.6 mm; median neck width, 6.3 mm) were treated with PED/coil. The median volume embolization ratio was 14.8%. The degree of angiographic filling at the 6-month and latest angiography showed complete occlusion in 60.5% (26/43) and 70.5% (31/44), respectively. Small (<?10 mm) aneurysms achieved a higher complete occlusion rate in the early period; a lower cumulative incidence of aneurysm occlusion was observed in large and giant (≥?10 mm) aneurysms (P?=?.024). The median clinical follow-up was 22 months, and no aneurysm ruptures occurred. Favorable clinical outcomes were achieved, with permanent neurological morbidity of 4.7% and no mortality. PED/coil demonstrated a high angiographic occlusion rate at an early stage. Loosely packed coils are sufficient to obliterate aneurysms effectively.

     

CalliSpheres载药微球栓塞治疗原发性肝细胞癌自发性破裂出血的有效性及安全性

目的 观察CalliSpheres载药微球治疗原发性肝细胞癌(PHC)自发性破裂出血的有效性及安全性。方法 对23例PHC自发性破裂出血患者以CalliSpheres载药微球(加载表柔比星)予以栓塞,之后酌情行TACE或靶向治疗等;监测心率、血压及血红蛋白,以判断止血效果;统计术中及术后不良反应及并发症发生率;于栓塞前及栓塞后3天、1个月检测肝功能。随访12个月,绘制K-M生存曲线,统计术后1、3、6、12个月生存率。结果 23例均顺利完成治疗,未见相关不良反应。栓塞后6 h心率较术前下降(P=0.001),血压及血红蛋白保持稳定未再下降,表明有效止血。栓塞后1~2天,17例出现轻微发热、恶心、呕吐、腹痛等栓塞综合征,经对症处理后均缓解;未见肝、肾衰竭及肝性脑病、胆道感染等严重并发症。栓塞后3天谷丙转氨酶(GPT)、谷草转氨酶(GOT)及总胆红素(TBil)均高于栓塞前及栓塞后1个月(P均<0.05),栓塞后1个月与栓塞前差异均无统计学意义(P均>0.05);各时间点白蛋白(ALB)差异无统计学意义(P>0.05)。栓塞后随访1~12个月,未见再次出血。栓塞后1、3、6及12个月,患者生存率为分别100%、82.61%、69.57%及56.52%。结论 CalliSpheres载药微球栓塞治疗PHC自发性破裂出血的有效性及安全性均较好。     

Pre-emptive nonselective perigraft aortic sac embolization with coils to prevent type II endoleak after endovascular aneurysm repair

ObjectivePre-emptive selective embolization of inferior mesenteric artery (IMA), lumbar arteries (LAs), and perigraft sac for prevention of type II endoleak (T2EL) has not been widely adopted. We perform pre-emptive nonselective perigraft aortic sac embolization with coils (PNPASEC) in patients at high risk for development of T2EL (four or more patent LAs, patent IMA ≥3 mm, and ≥30-mm aortic flow lumen). The goal of this study was to see whether PNPASEC decreases T2ELs requiring reinterventions.MethodsAll 266 patients undergoing elective endovascular aneurysm repair between September 1, 2007, and October 31, 2015, were retrospectively evaluated from a prospectively maintained database. Patients (N = 212; 211 men) with preoperative and postoperative contrast-enhanced computed tomography scans were included. Our PNPASEC technique involves leaving a wire in the sac after cannulation of the contralateral gate and inserting large (0.035-inch) coils into the sac after bifurcated graft deployment. T2EL and reintervention rates were compared between patients who underwent PNPASEC (group I) and those who met the criteria but did not have PNPASEC (group II) and those who did not meet the criteria (Group III).ResultsForty-seven (22.2%) patients were PNPASEC candidates and 165 (77.8%) patients (group III) were not. Among PNPASEC candidates, 16 (7.5%) underwent PNPASEC (group I) and 31 (14.6%) did not (group II). There were no significant differences between groups in terms of comorbidities, aneurysm size, and anatomic and neck characteristics. Mean number of patent LAs was similar between group I (4.5 ± 0.8) and group II (4.5 ± 0.9), which was significantly greater than in group III (1.9 ± 1.3; P < .001); 43.6% of group III patients had patent IMA. Mean follow-up was 44 ± 25 months. T2EL at 6 months was observed in 48.4% in group II, 3.0% in group III, and 6.3% in group I (P < .001). Sac diameter increase was seen in 38.7% in group II vs 6.1% in group III and 6.3% in group I (P < .001), with complete sac shrinkage in 23.3% in group II vs 23.8% in group III and 50.0% in group I (P = .09). T2EL-related interventions were performed in 29.0% in group II vs 1.2% in group III and 6.3% in group I (P < .001). Any endoleak at last follow-up was seen in 25.8% in group II vs 2.4% in group III and none in group I (P < .001).ConclusionsNonselective perigraft sac coil embolization in patients at high risk for T2EL (20% of patients undergoing endovascular aneurysm repair) is effective in preventing development of T2EL and is associated with decrease in sac size and reintervention rates.     

Mid-term outcome of intracranial aneurysms treated with HydroSoft coils compared to historical controls treated with bare platinum coils: a single-center experience

Background

HydroSoft (MicroVention, Aliso Viejo, CA), a hydrogel-platinum coil hybrid device, is one of various efforts to overcome recanalization of coiled intracranial aneurysms. The purpose of this study was to evaluate the efficacy and safety of the HydroSoft coils in patients with intracranial aneurysms, and to compare the 12-month outcomes with that of bare platinum coils.

Methods

Four-hundred one patients harboring 430 intracranial aneurysms underwent endovascular embolization with the HydroSoft coils. In the control group, 221 patients harboring 253 aneurysms underwent coil embolization with bare platinum coils. The authors compared the degree of occlusion of the aneurysms, packing attenuations, procedural-related complications, and 12-month follow-up results between the two groups.

Results

There were no significant differences of initial angiographic outcomes and procedure-related complications between the HydroSoft-coil group and the bare-coil group. Mean volumetric packing density of the HydroSoft-coil group was significantly higher than that of the bare platinum coil group (36.0?±?8.50 % versus 32.1?±?8.22 %, p?p?=?0.001, Fischer’s exact test). Multivariate Poisson regression revealed that coil embolization using the HydroSoft coil significantly reduces the retreatment rate of coiled aneurysms at 12-month follow-up (adjusted RR, 0.21; 95 % CI, 0.07-0.64; p?=?0.004).

Conclusion

Coil embolization using HydroSoft coils achieves higher volumetric packing density. Twelve-month follow-up data favors HydroSoft coils, with lower retreatment rates.     

对比Viabahn覆膜支架与金属裸支架治疗股腘动脉硬化闭塞症效果:Meta分析

目的 采用meta分析方法对比Viabahn覆膜支架与金属裸支架（BMS）治疗股腘动脉硬化闭塞症（ASO）的效果。方法 检索筛选中国生物医学文献数据库、万方医学网、中国知网、Embase、Web of Science、Cochrane Library和PubMed数据库关于以Viabahn覆膜支架（Viabahn组）及BMS （BMS组）治疗股腘ASO的随机对照研究,检索时间为建库至2022年4月30日;依据纳入及排除标准筛选文献。采用Cochrane RevMan 5.3软件分析组间技术成功率、12个月一/二期通畅率、靶病变血管重建（TLR）率和/或截肢率。结果 最终纳入9篇文献,含Viabahn组424例、BMS组469例共893例患者。Viabahn组12个月一期通畅率高于BMS组[比值比（OR）=1.90,95%CI（1.23,2.92）,P=0.004],而其TLR率低于BMS组[OR=0.44,95%CI（0.26,0.76）,P=0.003],组间技术成功率[风险差异（RD）=0,95%CI（－0.01,0.02）,P=0.59]、12个月二期通畅率[OR=1.48,95%CI（0.96,2.29）,P=0.07]及截肢率[RD=0,95%CI（－0.02,0.03）,P=0.79]差异均无统计学意义。结论 Viabahn覆膜支架及BMS用于治疗股腘动脉ASO可提高12个月一期通畅率、降低TLR率,二者12个月二期通畅率及截肢率相当。     

Contralateral vertebral approach for stenting and coil embolization of a large, thrombosed vertebral-posterior inferior cerebellar artery aneurysm. Case report

The authors report the successful staged stenting and coil embolization of a large vertebral artery-posterior inferior cerebellar artery (VA-PICA) aneurysm using the contralateral VA for access. A 67-year-old woman presented with a large ruptured VA-PICA aneurysm. Initial attempts to stent the wide-necked aneurysm from the ipsilateral side failed, so coil embolization of the dome was performed. During a second endovascular session, the aneurysm neck was successfully stented from the contralateral VA into the PICA. Six weeks later, coils were inserted into the aneurysm from the ipsilateral side. The coil result was stable at the 3-month follow-up examination.     

经导管弹簧圈栓塞治疗脾动脉瘤

目的探讨经导管弹簧圈栓塞治疗脾动脉瘤的临床应用价值。方法回顾性分析接受经导管弹簧圈栓塞治疗的18例脾动脉瘤患者的资料,其中真性脾动脉瘤14例,假性脾动脉瘤4例;近端型6例,中间型4例,脾门型8例。根据患者脾动脉造影情况,选择普通弹簧圈、微弹簧圈或机械可脱式弹簧圈进行栓塞。术后1周及1、3、9个月行CT增强或CTA复查,随后每月行电话随访。结果对18例均顺利完成手术,11例采用隔绝旷置术,4例采用瘤腔填塞术,3例采用隔绝旷置术+瘤腔填塞术。术后12例出现栓塞后综合征,其中8例出现不同程度的脾梗死,梗死体积约10%~35%;余4例为轻微并发症。随访中无瘤体增大、破裂或复发及相关并发症。结论经导管弹簧圈栓塞治疗脾动脉瘤简单可行、安全有效。